Jose Zavaleta
Endocrinology, Diabetes & Metabolism · Houston, TXNPI 1356444681
Payments from drug & device makers
Across 837 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- AstraZeneca$2K
- Novo Nordisk$1K
- Dexcom, Inc.$1K
- Mannkind Corporation$1K
- Boehringer Ingelheim$819
- plus $8K from 50 others
What the payments were for
- Food & beverage$15,16195%
- Education$1301%
- Gifts$1191%
- Other$6284%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$242
- CYCLOSET$153
- Vascepa$143
- AFREZZA$125
- TOUJEO$107
- SOLIQUA 100/33$107
How this compares
$16,038 in reported general payments places this provider in the 70th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 160 | $294,717 |
| JardianceEmpagliflozin | 125 | $168,666 |
| TrulicityDulaglutide | 82 | $166,333 |
| FarxigaDapagliflozin Propanediol | 89 | $118,644 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 69 | $103,601 |
| Tresiba Flextouch U-200Insulin Degludec | 62 | $46,445 |
| MounjaroTirzepatide | 31 | $45,038 |
| Xigduo XrDapaglifloz Propaned/Metformin | 30 | $42,284 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 30 | $35,653 |
| RybelsusSemaglutide | 13 | $24,728 |
| TradjentaLinagliptin | 21 | $23,954 |
| KerendiaFinerenone | 14 | $20,735 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $18,138 |
| LinzessLinaclotide | 22 | $16,934 |
| VascepaIcosapent Ethyl | 26 | $15,906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,309 | $319,445173 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Trijardy Xr | $819 | $304,339228 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,985 | $211,371113 claims |
| AstraZenecaFarxiga | $1,502 | $118,64489 claims |
| MerckJanumet Xr, Janumet | $301 | $53,79143 claims |
| BayerKerendia | $489 | $20,73514 claims |
| AbbVieLinzess, Synthroid | $674 | $19,84764 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $779 | $12,28616 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $356 | $2,095210 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Houston
- Maria CabanillasHouston$16.4M
- Damaris VegaHouston$12.3M
- Amer Al KaradshehHouston$8.8M
- Amir HassanHouston$5.2M
- Camilo JimenezHouston$5M
- Rocio HarbisonHouston$3.2M
- Gerardo BuesoHouston$1.2M
- Veena WatweHouston$976K
- Andres SplenserHouston$923K
- Prashant KoshyHouston$795K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.